Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study

Min-Ke He, Yong Le, Qi-Jiong Li, Zi-Shan Yu, Shao-Hua Li, Wei Wei, Rong-Ping Guo, Ming Shi, Min-Ke He, Yong Le, Qi-Jiong Li, Zi-Shan Yu, Shao-Hua Li, Wei Wei, Rong-Ping Guo, Ming Shi

Abstract

Background: Transarterial chemoembolization (TACE) is recommended as the standard care for unresectable hepatocellular carcinoma (HCC) at Barcelona Clinic Liver Cancer (BCLC) stage A-B. However, the efficacy of TACE on large (≥ 10 cm) stage A-B HCC is far from satisfactory, and it is proposed that hepatic artery infusion chemotherapy (HAIC) might be a better first-line treatment of this disease. Hence, we compared the safety and efficacy of HAIC with the modified FOLFOX (mFOLFOX) regimen and those of TACE in patients with massive unresectable HCC.

Methods: A prospective, non-randomized, phase II study was conducted on patients with massive unresectable HCC. The protocol involved HAIC with the mFOLFOX regimen (oxaliplatin, 85 mg/m2 intra-arterial infusion; leucovorin, 400 mg/m2 intra-arterial infusion; and fluorouracil, 400 mg/m2 bolus infusion and 2400 mg/m2 continuous infusion) every 3 weeks and TACE with 50 mg of epirubicin, 50 mg of lobaplatin, 6 mg of mitomycin, and lipiodol and polyvinyl alcohol particles. The tumor responses, time-to-progression (TTP), and safety were assessed.

Results: A total of 79 patients were recruited for this study: 38 in the HAIC group and 41 in the TACE group. The HAIC group exhibited higher partial response and disease control rates than did the TACE group (52.6% vs. 9.8%, P < 0.001; 83.8% vs. 52.5%, P = 0.004). The median TTPs for the HAIC and TACE groups were 5.87 and 3.6 months (hazard radio [HR] = 2.35, 95% confidence interval [CI] = 1.16-4.76, P = 0.015). More patients in the HAIC group than in the TACE group underwent resection (10 vs. 3, P = 0.033). The proportions of grade 3-4 adverse events (AE) and serious adverse events (SAE) were lower in the HAIC group than in the TACE group (grade 3-4 AEs: 13 vs. 27, P = 0.007; SAEs: 6 vs. 15, P = 0.044). More patients in the TACE group than in the HAIC group had the study treatment terminated early due to intolerable treatment-related adverse events or the withdrawal of consent (10 vs. 2, P = 0.026).

Conclusions: HAIC with mFOLFOX yielded significantly better treatment responses and less serious toxicity than did TACE. HAIC might represent a feasible and promising first-line treatment for patients with massive unresectable HCC.

Keywords: Hepatic artery infusion chemotherapy; Hepatocellular carcinoma; Transarterial chemoembolization; mFOLFOX.

Figures

Fig. 1
Fig. 1
Flow diagram of patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE. HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; AEs adverse events
Fig. 2
Fig. 2
Kaplan-Meier estimated progression-free survival curves of patients with unresectable hepatocellular carcinoma. Of the 79 patients, 38 underwent HAIC, and 41 underwent TACE. HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization

References

    1. Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35(1):73. doi: 10.1186/s40880-016-0137-8.
    1. Bruix J, Sherman M, American Association for the Study of Liver D Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi: 10.1002/hep.24199.
    1. European Association For The Study Of The L, European Organisation For R, Treatment Of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001.
    1. Verslype C, Rosmorduc O, Rougier P, Group EGW Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii41–48. doi: 10.1093/annonc/mds225.
    1. Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R. Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut. 1996;38(1):125–128. doi: 10.1136/gut.38.1.125.
    1. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97(4):1042–1050. doi: 10.1002/cncr.11111.
    1. Li S, Zhang L, Huang ZM, Wu PH. Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma. Chin J Cancer. 2015;34(6):254–263.
    1. Xue T, Le F, Chen R, Xie X, Zhang L, Ge N, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3):64. doi: 10.1007/s12032-015-0504-3.
    1. Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23(1):129–135. doi: 10.1111/j.1365-2036.2006.02704.x.
    1. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol. 2000;73(2):109–114. doi: 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>;2-J.
    1. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol. 2003;181(5):1327–1334. doi: 10.2214/ajr.181.5.1811327.
    1. Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16(4):355–361. doi: 10.3350/kjhep.2010.16.4.355.
    1. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, et al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. European J Surg Oncol. 2006;32(2):201–207. doi: 10.1016/j.ejso.2005.11.003.
    1. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51(6):1030–1036. doi: 10.1016/j.jhep.2009.09.004.
    1. Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol. 2011;46(3):359–366. doi: 10.1007/s00535-010-0306-5.
    1. Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105(1):59–68. doi: 10.1093/jnci/djs464.
    1. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol. 2002;29(2):119–125. doi: 10.1053/sonc.2002.31679.
    1. Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50(4):445–454. doi: 10.1007/s00535-014-0978-3.
    1. Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver Cancer. 2015;4(4):228–240. doi: 10.1159/000367737.
    1. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904–1907. doi: 10.1038/bjc.2013.542.
    1. Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, et al. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS ONE. 2014;9(5):e92784. doi: 10.1371/journal.pone.0092784.
    1. Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med. 2013;2(1):86–98. doi: 10.1002/cam4.55.
    1. Cassidy J. Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract. 2000;54(6):399–402.
    1. Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M, et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer. 1997;33(9):1400–1406. doi: 10.1016/S0959-8049(97)00122-6.
    1. Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, et al. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62(1):91–96. doi: 10.1016/j.ijrobp.2004.09.009.
    1. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–3508. doi: 10.1200/JCO.2012.44.5643.
    1. Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58(1):81–88. doi: 10.1016/j.jhep.2012.09.006.
    1. Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, et al. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010;33(1):43–46. doi: 10.1097/COC.0b013e31819d8668.
    1. Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3970–3977. doi: 10.3748/wjg.v21.i13.3970.
    1. Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12(5):599–603. doi: 10.1023/A:1011186708754.
    1. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481) J Clin Oncol. 2006;24(9):1395–1403. doi: 10.1200/JCO.2005.03.8166.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. doi: 10.1097/00000421-198212000-00014.
    1. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001;37(1):1–3. doi: 10.1002/mpo.1154.
    1. The National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). . Accessed 25 Apr 2012.
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi: 10.1055/s-0030-1247132.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner